+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers

  • ID: 4876668
  • Report
  • October 2019
  • Region: Global
  • 375 Pages
  • Roots Analysis

Enquire about COVID-19 updates for this product.

Enquire Now
Advances in the Field of Biotechnology have Enabled the Establishment of Several Minimally Invasive / Non-Invasive Approaches for Disease Diagnosis

FEATURED COMPANIES

  • 360 Capital Partners
  • BioDiscovery
  • EDP Biotech
  • IPS Genomix
  • Nonacus
  • Savicell Diagnostics
  • MORE

Cancer is known to be one of the leading causes of death worldwide.
In 2019, 0.6 million deaths due to cancer are estimated in the US alone.  Moreover, the World Health Organization has estimated the number of new cancer cases to rise by 70% over the next 20 years.  One of the primary reasons for the high mortality associated with this condition is believed to be late diagnosis. This results in delayed treatment, which severely compromises chances of survival. For many years, tissue biopsy has been considered the gold standard for cancer diagnosis. However, owing to the invasive nature of the test, biopsies cannot be repeated frequently to assess / measure disease progression or monitor therapeutic outcome. In fact, in some cases, it is not possible to carry out a biopsy because the affected tissue / organ is not amenable to undergo such a painful and traumatic procedure. This has resulted in a significant unmet need for safer and more patient friendly cancer diagnostics that are capable of offering accurate test results.

Advances in the field of biotechnology have enabled the establishment of several minimally invasive / non-invasive approaches for disease diagnosis.
Amongst other promising diagnostic tools, liquid biopsy has emerged as a versatile and promising non-invasive cancer diagnostic tool. This procedure is based on the analysis of biofluids (such as blood, urine and / or plasma) in order to detect rare forms of biomarkers / tumor markers, such as circulating tumor cells (CTCs), circulating tumor DNA / RNA (ctNAs), circulating free DNA (cfDNA) and exosomes. Moreover, liquid biopsies have been demonstrated to be capable of assessing the stage of tumor at the time of sample extraction. Additionally, owing to the non-invasive nature of the test, it can be actively used to monitor / track changes in tumors, both before and during the course of treatment. Other than liquid biopsy, the cancer diagnostics market has witnessed the emergence of several other non-invasive diagnostic technologies, which are based on analytes that are either superficially located (such as skin lesions) and / or are expelled from the body (such as bronchial fluids and exhaled breath). Most of the non-invasive diagnostic techniques mentioned above are backed by clinical data, validating their relevance and applicability across several types of solid tumors (such as breast cancer, lung cancer, ovarian cancer and pancreatic cancer) and hematological malignancies (such as leukemia and lymphoma). In future, non-invasive cancer diagnosis methods, particularly liquid biopsies, are anticipated to replace the existing invasive diagnostic techniques.
Scope of the Report

The 'Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030:

Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers' report provides an extensive study on liquid biopsy kits / assays that are either commercialized or are under development for diagnosis and / or monitoring of different types of cancer. In addition, it features an elaborate discussion on the likely future opportunity associated with such tests, over the next 10 years. Amongst other elements, the report includes:

  • A detailed review of the overall landscape of the non-invasive cancer diagnostics market, featuring information on the developers of such products and analyses based on a number of relevant parameters, such as year of establishment, company size, geographical location, current development status of proprietary liquid biopsy test (under development, research use only, and available), type of product (assay kit, software / algorithm and device), type of tumor marker analyzed (CTCs, ctDNA, cfDNA, exosomes, and others), key applications (early diagnosis, treatment selection, patient monitoring and recurrence monitoring), type of analyte used (blood, urine and others) and target cancer indications.
  • An analysis of the various partnerships pertaining to non-invasive cancer diagnostics, which have been established between 2016 and 2019, based on various parameters, such as type of partnership, year of partnership, type of tumor marker, target cancer indications and the most active players.
  • An analysis of the investments made in companies engaged in the development of non-invasive cancer diagnostics, including details of seed financing, venture capital financing, debt financing, grants, and capital raised via IPOs and subsequent public offerings.
  • An analysis of the initiatives of big pharma players , highlighting the key focus areas of such companies and analysis based on various relevant parameters, such as stage of development of their proprietary non-invasive cancer diagnostic test(s), key applications, type of tumor marker and target disease indications.
  • A detailed acquisition target analysis, taking into consideration the historical trend of the activity of the companies that have acquired other firms since 2016, and offering a means for other industry stakeholders to identify potential acquisition targets.
  • Elaborate profiles of the key players engaged in this domain, featuring a brief overview of the company, its financial information (if available), a detailed description of its product portfolio, recent developments and an informed future outlook.

One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for non-invasive cancer diagnostics.
Based on various parameters, such as number of available / under development products and estimated annual adoption rates, we have provided an informed estimate on the likely evolution of the market over the period 2019-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] type of tumor marker (ctDNA, cfDNA, CTCs, exosomes, and others), [B] key applications (early diagnosis, patient monitoring and recurrence monitoring), [C] target disease indications (breast cancer, lung cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, gastric cancer, pancreatic cancer, ovarian cancer, and others), [D] end users (hospitals, research institutes and others), and [E] key geographical regions (the US, the UK, Germany, Italy, Spain, France, Japan, Australia, China, India, and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Shibichakravarthy Kannan, Founder and CEO, Theranosis Life Sciences
  • Abizar Lakdawalla, Founder, ProXeom
  • Philippe Nore, CEO and Co-founder, MiNDERA Corporation
  • Frank Szczepanski, President and CEO, IVDiagnostics
  • Mark Li, CEO, Resolution Bioscience
  • Brad Walsh, CEO, Minomic International
  • Joachim Fluhrer, Founder and Medical Director, GenosticsAnton Iliuk, President and Chief Technology Officer, Tymora Analytical Operations
  • Burkhard Jansen, Chief Medical Officer, DermTech
  • Christer Ericsson, Chief Scientific Officer, iCellate Medical
  • Jake Micallef, Chief Scientific Officer, VolitionRx
  • Nathalie Bernard, Marketing Director, OncoDNA
  • Riccardo Razzini, Sales and Marketing Manager, LCM Genect
  • Peter French, Strategic Technology Advisor, Sienna Cancer Diagnostics

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 360 Capital Partners
  • BioDiscovery
  • EDP Biotech
  • IPS Genomix
  • Nonacus
  • Savicell Diagnostics
  • MORE

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Cancer-related Statistics and Current Disease Burden
3.3. Importance of Early Cancer Detection
3.4. Cancer Screening and Diagnosis
3.5. Conventional Methods of Cancer Diagnosis
3.5.1. Biopsy
3.5.1.1. Fine Needle Aspiration Biopsy
3.5.1.2. Core Needle Biopsy
3.5.1.3. Vacuum-Assisted Biopsy
3.5.1.4. Image-Guided Biopsy
3.5.1.5. Sentinel Node Biopsy
3.5.1.6. Surgical Biopsy
3.5.1.7. Endoscopic Biopsy
3.5.1.8. Bone Marrow Biopsy
3.5.2. Endoscopy
3.6. Need for Non-Invasive Cancer Diagnostics
3.7. Liquid Biopsy and Other Non-Invasive Cancer Diagnostics
3.7.1. Liquid Biopsy
3.7.1.1. Relevance and Analysis of Circulating Tumor Cells
3.7.1.2. Relevance and Analysis of Circulating Tumor DNA
3.7.1.3. Relevance and Analysis of Exosomes
3.7.2. Other Non-Invasive Cancer Diagnostics
3.7.3. Benefits of Non-Invasive Cancer Diagnostics
3.7.4. Emerging Trends in Intellectual Property Related to Non-Invasive Cancer Diagnostics
3.7.5. Challenges Associated with Non-Invasive Cancer Diagnostics
3.8. Future Perspectives
 
4. NON-INVASIVE CANCER SCREENING AND DIAGNOSIS
4.1. Chapter Overview
4.2. Diagnostic Imaging
4.2.1. Magnetic Resonance Imaging
4.2.2. Mammography
4.2.3. Bone Scan
4.2.4. Computerized Tomography (CT) Scan
4.2.5. Integrated Positron Emission Tomography (PET)-CT Scan
4.2.6. Ultrasound
4.2.7. X-ray Radiography (Barium Enema)
4.3. Screening Assays
4.3.1. Circulating Tumor Marker Test
4.3.2. Digital Rectal Exam (DRE)
4.3.3. Fecal Occult Blood Test (FOBT)
4.3.4. Multigated Acquisition (MUGA) Scan
4.3.5. Human Papilloma Virus Test and Papanicolaou Test
4.4. Advanced Non-Invasive Approaches
4.4.1. Cytogenetic / Gene Expression Studies
4.4.2. Molecular Signature-based Non-Invasive Methods
4.4.3. Saliva-based Oral Cancer Diagnostics
4.4.4. Vital Staining
4.4.5. Optical Biopsy
4.4.6. Other Diagnostic Techniques
 
5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Liquid Biopsy Products: List of Developers
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size and Geographical Location
5.2.3. Leading Players: Analysis by Number of Products
5.3. Liquid Biopsy Products: List of Available / Under Development Products
5.3.1. Analysis by Application Area
5.3.2. Analysis by Target Cancer Indication
5.3.3. Analysis by Type of Tumor Marker
5.3.4. Analysis by Type of Analyte
5.3.5. Analysis by Status of Development
5.4. Liquid Biopsy Products: Affiliated Technology Platforms, Systems and Instruments
5.5. Liquid Biopsy Products: List of Contract Service Providers
 
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Amoy Diagnostics
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Liquid Biopsy Product Portfolio
6.2.4. Recent Developments and Future Outlook
6.3. DiaCarta
6.3.1. Company Overview
6.3.2. Liquid Biopsy Product Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. HaploX
6.4.1. Company Overview
6.4.2. Liquid Biopsy Product Portfolio
6.4.3. Recent Developments and Future Outlook
6.5. NeoGenomics
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Liquid Biopsy Product Portfolio
6.5.4. Recent Developments and Future Outlook
6.6. QIAGEN
6.6.1. Company Overview
6.6.2. Financial Information
6.6.3. Liquid Biopsy Product Portfolio
6.6.4. Recent Developments and Future Outlook
6.7. Swift Biosciences
6.7.1. Company Overview
6.7.2. Liquid Biopsy Product Portfolio
6.7.3. Recent Developments and Future Outlook
6.8. Sysmex Inostics
6.8.1. Company Overview
6.8.2. Liquid Biopsy Product Portfolio
6.8.3. Recent Developments and Future Outlook
6.9. Thermo Fisher Scientific
6.9.1. Company Overview
6.9.2. Financial Information
6.9.3. Liquid Biopsy Product Portfolio
6.9.4. Recent Developments and Future Outlook
 
7. NON-INVASIVE CANCER DIAGNOSTICS-RELATED INITIATIVES OF BIG PHARMA PLAYERS
7.1. Chapter Overview
7.2. Top Pharmaceutical Companies
7.2.1. Analysis by Application Area
7.2.2. Analysis by Target Cancer Indication
7.2.3. Analysis by Type of Tumor Marker
7.2.4. Analysis by Status of Development of Product
 
8. KEY ACQUISITION TARGETS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Potential Strategic Acquisition Targets: Analysis by Geography
8.3.1. Potential Strategic Acquisition Targets in North America
8.3.1.1. Scoring Criteria
8.3.1.2. Likely Targets
8.3.2. Potential Strategic Acquisition Targets in Europe
8.3.2.1. Scoring Criteria
8.3.2.2. Likely Targets
8.3.3. Potential Strategic Acquisition Targets in Asia-Pacific
8.3.3.1. Scoring Criteria
8.3.3.2. Likely Targets
8.3.4. Potential Strategic Acquisition Targets in Rest of the World
8.3.4.1. Scoring Criteria
8.3.4.2. Likely Targets
8.4. Potential Strategic Acquisition Targets: Analysis by Product Portfolio
8.4.1. Scoring Criteria
8.4.2. Likely Targets
 
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Type of Tumor Marker
9.3.4. Analysis by Target Cancer Indication
9.3.5. Analysis by Type of Partner
9.3.6. Most Active Players: Analysis by Number of Partnerships
9.3.7. Regional Analysis
9.3.7.1. Intercontinental and Intracontinental Partnerships
 
10. FUNDING AND INVESTMENT ANALYSIS
10.1. Chapter Overview
10.2. Types of Funding
10.3. List of Funding and Investment Instances
10.3.1. Analysis by Number of Funding Instances
10.3.2. Analysis by Amount Invested
10.3.3. Analysis by Type of Funding
10.3.4. Analysis by Type of Target Cancer Indication
10.3.5. Analysis by Tumor Marker
10.3.6. Most Active Players: Analysis by Amount Invested
10.3.7. Most Active Investors: Analysis by Number of Funding Instances
10.3.8. Regional Analysis by Amount Invested
10.4. Concluding Remarks
 
11. OTHER NON-INVASIVE CANCER DIAGNOSTICS
11.1. Chapter Overview
11.2. Non-Blood-based Biomarker Detection Tests
11.3. DNA Methylation-based Tests
11.4. FOBT and Fecal Immunochemical Tests (FIT)
11.5. MicroRNA (miRNA)-based Tests
11.6. Pigmented Lesion Assays
11.7. Stool DNA (sDNA)-based Tests
11.8. Volatile Organic Compound (VOC) Detection Tests
11.9. Other Non-Invasive Cancer Diagnostics
 
12. SURVEY ANALYSIS
12.1. Chapter Overview
12.2. Other Non-Invasive Cancer Diagnostics: Survey Analysis
12.2.1. Overview of Respondents
12.2.2. Designation of Respondents
12.2.3. Product Portfolio
12.2.4. Type of Product / Service Offered
12.2.5. Application Area
12.2.6. Status of Development of Product
12.2.7. Likely Market Size
 
13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Forecast Methodology
13.3. Global Non-Invasive Cancer Diagnostics Market, 2019-2030
13.3.1. Global Liquid Biopsy Market, 2019-2030
13.3.1.1. Global Liquid Biopsy Market: Distribution by Application Area, 2019-2030
13.3.1.1.1. Global Liquid Biopsy Market for Early Diagnosis, 2019-2030
13.3.1.1.2. Global Liquid Biopsy Market for Patient Monitoring, 2019-2030
13.3.1.1.3. Global Liquid Biopsy Market for Recurrence Monitoring, 2019-2030
13.3.1.2. Global Liquid Biopsy Market: Distribution by Target Cancer Indication, 2019-2030
13.3.1.2.1. Global Liquid Biopsy Market for Breast Cancer, 2019-2030
13.3.1.2.2. Global Liquid Biopsy Market for Lung Cancer, 2019-2030
13.3.1.2.3. Global Liquid Biopsy Market for Colorectal Cancer, 2019-2030
13.3.1.2.4. Global Liquid Biopsy Market for Prostate Cancer, 2019-2030
13.3.1.2.5. Global Liquid Biopsy Market for Bladder Cancer, 2019-2030
13.3.1.2.6. Global Liquid Biopsy Market for Melanoma, 2019-2030
13.3.1.2.7. Global Liquid Biopsy Market for Gastric Cancer, 2019-2030
13.3.1.2.8. Global Liquid Biopsy Market for Pancreatic Cancer, 2019-2030
13.3.1.2.9. Global Liquid Biopsy Market for Ovarian Cancer, 2019-2030
13.3.1.2.10. Global Liquid Biopsy Market for Other Cancers, 2019-2030
13.3.1.3. Global Liquid Biopsy Market: Distribution by Type of Tumor Marker, 2019-2030
13.3.1.3.1. Global Liquid Biopsy Market for ctDNA, 2019-2030
13.3.1.3.2. Global Liquid Biopsy Market for cfDNA, 2019-2030
13.3.1.3.3. Global Liquid Biopsy Market for CTCs, 2019-2030
13.3.1.3.4. Global Liquid Biopsy Market for Exosomes, 2019-2030
13.3.1.3.5. Global Liquid Biopsy Market for Other Tumor Markers, 2019-2030
13.3.1.4. Global Liquid Biopsy Market: Distribution by Type of Analyte, 2019-2030
13.3.1.4.1. Global Liquid Biopsy Market for Blood, 2019-2030
13.3.1.4.2. Global Liquid Biopsy Market for Other Body Fluids, 2019-2030 (USD Billion)
13.3.1.5. Global Liquid Biopsy Market: Distribution by End User, 2019-2030
13.3.1.5.1. Global Liquid Biopsy Market for Hospitals, 2019-2030
13.3.1.5.2. Global Liquid Biopsy Market for Research Institutes, 2019-2030
13.3.1.5.3. Global Liquid Biopsy Market for Other End User, 2019-2030
13.3.1.6. Global Liquid Biopsy Market: Distribution by Geography, 2019-2030
13.3.1.6.1 Liquid Biopsy Market in the US, 2019-2030
13.3.1.6.2 Liquid Biopsy Market in the UK, 2019-2030
13.3.1.6.3 Liquid Biopsy Market in Germany, 2019-2030
13.3.1.6.4 Liquid Biopsy Market in Italy, 2019-2030
13.3.1.6.5 Liquid Biopsy Market in Spain, 2019-2030
13.3.1.6.6 Liquid Biopsy Market in France, 2019-2030
13.3.1.6.7 Liquid Biopsy Market in Japan, 2019-2030
13.3.1.6.8 Liquid Biopsy Market in Australia, 2019-2030
13.3.1.6.9 Liquid Biopsy Market in China, 2019-2030
13.3.1.6.10 Liquid Biopsy Market in India, 2019-2030
13.3.1.6.11 Liquid Biopsy Market in Rest of the World, 2019-2030
13.3.2. Other Non-Invasive Cancer Diagnostics Market Forecast, 2019-2030
 
14. CONCLUSION
14.1. Chapter Overview
14.2. Key Takeaways
 
15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Genostics
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Joachim Fluhrer, Founder and Medical Director
15.3. Theranosis Life Sciences
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Shibichakravarthy Kannan, Founder and CEO
15.4. Proxeom
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Abizar Lakdawalla, Founder
15.5. MiNDERA
15.5.1. Company Snapshot
15.5.2. Interview Transcript: Philippe Nore, CEO and Co-founder
15.6. IVDiagnostics
15.6.1. Company Snapshot
15.6.2. Interview Transcript: Frank Szczepanski, President and CEO
15.7. Resolution Bioscience
15.7.1. Company Snapshot
15.7.2. Interview Transcript: Mark Li, CEO
15.8. Minomic International
15.8.1. Company Snapshot
15.8.2. Interview Transcript: Brad Walsh, CEO
15.9. Nanostics
15.9.1. Company Snapshot
15.9.2. Interview Transcript: Catalina Vasquez, Chief Operating Officer
15.10. Tymora Analytical Operations
15.10.1. Company Snapshot
15.10.2. Interview Transcript: Anton Iliuk, President and Chief Technology Officer
15.11. DermTech
15.11.1. Company Snapshot
15.11.2. Interview Transcript: Burkhard Jansen, Chief Medical Officer
15.12. iCellate Medical
15.12.1. Company Snapshot
15.12.2. Interview Transcript: Christer Ericsson, Chief Scientific Officer
15.13. VolitionRx
15.13.1. Company Snapshot
15.13.2. Interview Transcript: Jake Micallef, Chief Scientific Officer
15.14. OncoDNA
15.14.1. Company Snapshot
15.14.2. Interview Transcript: Nathalie Bernard, Marketing Director
15.15. LCM Genect
15.15.1. Company Snapshot
15.15.2. Interview Transcript: Riccardo Razzini, Sales and Marketing Manager
15.16. Sienna Cancer Diagnostics
15.16.1. Company Snapshot
15.16.2. Interview Transcript: Peter French, Strategic Technology Advisor
 
16. APPENDIX 1: TABULATED DATA
 
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

LIST OF FIGURES

Figure 3.1. Global Cancer Incidence Statistics: Distribution by Indication
Figure 3.2. Lung Cancer: Estimated New Cases in 2018 (in Thousands)
Figure 3.3. Breast Cancer: Estimated New Cases in 2018 (in Thousands)
Figure 3.4. Colorectal Cancer: Estimated New Cases in 2018 (in Thousands)
Figure 3.5. Factors Affecting Cancer Screening
Figure 3.6. Conventional Cancer Diagnosis Methods
Figure 3.7. Disadvantages of Conventional Cancer Diagnosis Methods
Figure 3.8. Circulating Biomarkers for Cancer Detection and Diagnosis
Figure 3.9. Traditional Biopsy: Procedure Overview
Figure 3.10. Non-Invasive Biopsy: Process Flow
Figure 3.11. Non-Invasive Cancer Diagnostics: Year-wise Distribution of Filed / Granted Patents
Figure 4.1. Broad Categories of Non-Invasive Cancer Screening and Diagnostics
Figure 4.2. Types of Diagnostic Imaging
Figure 4.3. Types of Screening Assays
Figure 4.4. Types of Advanced Non-Invasive Approaches for Cancer Diagnosis
Figure 5.1. Liquid Biopsy Developers: Distribution by Year of Establishment
Figure 5.2. Liquid Biopsy Developers: Distribution by Company Size and Geographical Location
Figure 5.3. Liquid Biopsy Developers: Leading Players
Figure 5.4. Liquid Biopsy Products: Distribution by Application Area
Figure 5.5. Liquid Biopsy Products: Distribution by Target Cancer Indication
Figure 5.6. Liquid Biopsy Products: Distribution by Type of Tumor Marker  
Figure 5.7. Liquid Biopsy Products: Distribution by Type of Analyte
Figure 5.8. Liquid Biopsy Products: Distribution Status of Development
Figure 6.1. Amoy Diagnostics: Annual Revenues, 2016 - 2018 (CNY Million)
Figure 6.2. NeoGenomics: Annual Revenues, 2014 - 2018 (EUR Million)
Figure 6.3. QIAGEN: Annual Revenues, 2014 - 2018 (EUR Billion)
Figure 6.4. Thermo Fisher Scientific: Annual Revenues, 2014 - 2018 (EUR Billion)
Figure 7.1. Big Pharma Players: Heat Map Analysis 
Figure 7.2. Big Pharma Players: Distribution by Application Area
Figure 7.3. Big Pharma Players: Distribution by Target Cancer Indication
Figure 7.4. Big Pharma Players: Distribution by Type of Tumor Marker
Figure 7.5. Big Pharma Players: Distribution by Status of Development of Product
Figure 9.1. Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2019
Figure 9.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3. Partnerships and Collaborations: Year-wise Trend by Type of Partnership, 2016-2019
Figure 9.4. Partnerships and Collaborations: Distribution by Type of Tumor Marker
Figure 9.5. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Tumor Marker
Figure 9.6. Partnerships and Collaborations: Distribution by Target Cancer Indication
Figure 9.7. Partnerships and Collaborations: Distribution by Type of Partnership and Target Cancer Indication
Figure 9.8. Partnerships and Collaborations: Year-wise Trend for Type of Partnership and Target Cancer Indication
Figure 9.9. Partnerships and Collaborations: Distribution by Year and Type of Partner
Figure 9.10. Most Active Players: Distribution by Number of Partnerships 
Figure 9.11. Partnerships and Collaborations: Regional Distribution
Figure 9.12. Partnerships and Collaborations: Intercontinental and Intracontinental Partnerships
Figure 10.1. Funding and Investments: Distribution of Industrial Players by Year of Establishment and Type of Funding, 2015-2019
Figure 10.2. Funding and Investments: Cumulative Year-wise Trend, 2015-2019
Figure 10.3. Funding and Investments: Cumulative Amount Invested by Year, 2015-2019 (USD Million)
Figure 10.4. Funding and Investments: Distribution by Type of Funding, 2015-2019
Figure 10.5. Funding and Investments: Distribution by Amount Invested and Type of Funding, 2015-2019 (USD Million)
Figure 10.6. Funding and Investments: Summary of Investments, 2015-2019 (USD Million)
Figure 10.7. Funding and Investments: Distribution by Target Cancer Indication
Figure 10.8. Funding and Investments: Distribution by Type of Tumor Marker 
Figure 10.9. Funding and Investments: Geographical Distribution by Number of Instances 
Figure 10.10. Funding and Investments: Regional Distribution of Funding Instances
Figure 10.11. Most Active Players: Distribution by Amount Invested 
Figure 10.12. Most Active Investors: Distribution by Number of Instances 
Figure 10.13. Funding and Investment Summary, 2015-2019 (USD Million)
Figure 12.1. Survey Analysis: Distribution by Geography
Figure 12.2. Survey Analysis: Distribution by Designation of Respondents
Figure 12.3. Survey Analysis: Distribution by Product Portfolio
Figure 12.4. Survey Analysis: Distribution by Type of Product / Service Offered
Figure 12.5. Survey Analysis: Distribution by Application Area
Figure 12.6. Survey Analysis: Distribution by Status of Development of Product
Figure 12.7. Survey Analysis: Likely Size of Liquid Biopsy Products Market (2030)
Figure 12.8. Survey Analysis: Likely Size of Other Non-Invasive Cancer Diagnostics Market (2030)
Figure 13.1. Global Non-Invasive Cancer Diagnostics Market, 2019-2030 (USD Billion)
Figure 13.2. Global Liquid Biopsy Market, 2019-2030 (USD Billion)
Figure 13.3. Global Liquid Biopsy Market: Distribution by Application Area, 2019-2030 (USD Billion)
Figure 13.4. Global Liquid Biopsy Market for Early Diagnosis, 2019-2030 (USD Billion)
Figure 13.5. Global Liquid Biopsy Market for Patient Monitoring, 2019-2030 (USD Billion)
Figure 13.6. Global Liquid Biopsy Market for Recurrence Monitoring, 2019-2030 (USD Billion)
Figure 13.7. Global Liquid Biopsy Market: Distribution by Target Cancer Indication, 2019-2030 (USD Billion)
Figure 13.8. Global Liquid Biopsy Market for Breast Cancer, 2019-2030 (USD Billion)
Figure 13.9. Global Liquid Biopsy Market for Lung Cancer, 2019-2030 (USD Billion)
Figure 13.10. Global Liquid Biopsy Market for Colorectal Cancer, 2019-2030 (USD Billion)
Figure 13.11. Global Liquid Biopsy Market for Prostate Cancer, 2019-2030 (USD Billion)
Figure 13.12. Global Liquid Biopsy Market for Bladder Cancer, 2019-2030 (USD Billion)
Figure 13.13. Global Liquid Biopsy Market for Melanoma, 2019-2030 (USD Billion)
Figure 13.14. Global Liquid Biopsy Market for Gastric Cancer, 2019-2030 (USD Billion)
Figure 13.15. Global Liquid Biopsy Market for Pancreatic Cancer, 2019-2030 (USD Billion)
Figure 13.16. Global Liquid Biopsy Market for Ovarian Cancer, 2019-2030 (USD Billion)
Figure 13.17. Global Liquid Biopsy Market for Other Cancers, 2019-2030 (USD Billion)
Figure 13.18. Global Liquid Biopsy Market: Distribution by Type of Tumor Marker, 2019-2030 (USD Billion)
Figure 13.19. Global Liquid Biopsy Market for ctDNA, 2019-2030 (USD Billion)
Figure 13.20. Global Liquid Biopsy Market for cfDNA, 2019-2030 (USD Billion)
Figure 13.21. Global Liquid Biopsy Market for CTCs, 2019-2030 (USD Billion)
Figure 13.22. Global Liquid Biopsy Market for Exosomes, 2019-2030 (USD Billion)
Figure 13.23. Global Liquid Biopsy Market for Other Tumor Markers, 2019-2030 (USD Billion)
Figure 13.24. Global Liquid Biopsy Market: Distribution by Type of Analyte, 2019-2030 (USD Billion)
Figure 13.25. Global Liquid Biopsy Market for Blood, 2019-2030 (USD Billion)
Figure 13.26. Global Liquid Biopsy Market for Other Body Fluids, 2019-2030 (USD Billion)
Figure 13.27. Global Liquid Biopsy Market: Distribution by End User, 2019-2030 (USD Billion)
Figure 13.28. Global Liquid Biopsy Market for Hospitals, 2019-2030 (USD Billion)
Figure 13.29. Global Liquid Biopsy Market for Research Institutes, 2019-2030 (USD Billion)
Figure 13.30. Global Liquid Biopsy Market for Other End User, 2019-2030 (USD Billion)
Figure 13.31. Global Liquid Biopsy Market: Distribution by Geography, 2019-2030 (USD Billion)
Figure 13.32. Liquid Biopsy Market in the US, 2019-2030 (USD Billion)
Figure 13.33. Liquid Biopsy Market in the UK, 2019-2030 (USD Billion)
Figure 13.34. Liquid Biopsy Market in Germany, 2019-2030 (USD Billion)
Figure 13.35. Liquid Biopsy Market in Italy, 2019-2030 (USD Billion)
Figure 13.36. Liquid Biopsy Market in Spain, 2019-2030 (USD Billion)
Figure 13.37. Liquid Biopsy Market in France, 2019-2030 (USD Billion)
Figure 13.38. Liquid Biopsy Market in Japan, 2019-2030 (USD Billion)
Figure 13.39. Liquid Biopsy Market in Australia, 2019-2030 (USD Billion)
Figure 13.40. Liquid Biopsy Market in China, 2019-2030 (USD Billion)
Figure 13.41. Liquid Biopsy Market in India, 2019-2030 (USD Billion)
Figure 13.42. Liquid Biopsy Market in India: Distribution by Application Area, 2019-2030 (USD Billion)
Figure 13.43. Liquid Biopsy Market in India: Distribution by Target Cancer Indication, 2019-2030 (USD Billion)
Figure 13.44. Liquid Biopsy Market in Rest of the World, 2019-2030 (USD Billion)
Figure 13.45. Other Non-Invasive Cancer Diagnostics Market, 2019-2030 (USD Billion)

LIST OF TABLES

Table 3.1. Survival on Early Diagnosis of Cancer
Table 3.2. Cost of Biopsy for Different Cancer Indications (in USD)
Table 3.3. Common Endoscopic Procedures
Table 4.1. Key Tumor Markers Analyzed in Liquid Biopsy
Table 5.1. Liquid Biopsy Products: List of Developers
Table 5.2. Liquid Biopsy Products: Distribution by Type of Application Area
Table 5.3. Liquid Biopsy Products: Technologies, Platforms, Systems and Instruments
Table 5.4. Liquid Biopsy Products: List of Service Providers
Table 6.1. Non-Invasive Cancer Diagnostics: List of Profiled Companies
Table 6.2. Amoy Diagnostics: Company Snapshot
Table 6.3. Amoy Diagnostics: Product Portfolio
Table 6.4. Amoy Diagnostics: Recent Developments and Future Outlook
Table 6.5. DiaCarta: Company Snapshot
Table 6.6. DiaCarta: Product Portfolio
Table 6.7. DiaCarta: Recent Developments and Future Outlook
Table 6.8. HaploX: Company Snapshot
Table 6.9. HaploX: Product Portfolio
Table 6.10. HaploX: Recent Developments and Future Outlook
Table 6.11. NeoGenomics: Company Snapshot
Table 6.12. NeoGenomics: Product Portfolio
Table 6.13. NeoGenomics: Recent Developments and Future Outlook
Table 6.14. QIAGEN: Company Snapshot
Table 6.15. QIAGEN: Product Portfolio
Table 6.16. QIAGEN: Recent Developments and Future Outlook
Table 6.17. Swift Biosciences: Company Snapshot
Table 6.18. Swift Biosciences: Product Portfolio
Table 6.19. Swift Biosciences: Recent Developments and Future Outlook
Table 6.20. Sysmex Inostics: Company Snapshot
Table 6.21. Sysmex Inostics: Product Portfolio
Table 6.22. Sysmex Inostics: Recent Developments and Future Outlook
Table 6.23. Thermo Fisher Scientific: Company Snapshot
Table 6.24. Thermo Fisher Scientific: Product Portfolio
Table 6.25. Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 8.1. North America: Most Likely Partners for Acquisition
Table 8.2. Europe: Most Likely Partners for Acquisition
Table 8.3. Asia-Pacific: Most Likely Partners for Acquisition
Table 8.4. Rest of the World: Most Likely Partners for Acquisition
Table 8.5. Most Likely Partners for Acquisition based on Product Portfolio
Table 9.1. Non-Invasive Cancer Diagnostics: Partnerships and Collaborations, 2016-2019
Table 10.1. Non-Invasive Cancer Diagnostics Market: Funding and Investments, 2015-2019
Table 10.2. Funding and Investment Analysis: Summary of Investments
Table 12.1. Survey Response: Overview of Respondents
Table 12.2. Survey Response: Designation of Respondents
Table 12.3. Survey Response: Product Portfolio
Table 12.4. Survey Response: Type of Product / Service Offered
Table 12.5. Survey Response: Application Area
Table 12.6. Survey Response: Status of Development of Product
Table 12.7. Survey Response: Likely Liquid Biopsy Market Size (2030)
Table 12.8. Survey Response: Likely Other Non-Invasive Cancer Diagnostics Market Size
Table 14.1. Non-Invasive Cancer Diagnostics: Summary of the Competitive Insights
Table 15.1. Genostics: Key Highlights
Table 15.2. Theranosis Life Sciences: Key Highlights
Table 15.3. ProXeom: Key Highlights
Table 15.4. MiNDERA: Key Highlights
Table 15.5. INDiagnostics: Key Highlights
Table 15.6. Resolution Bioscience: Key Highlights
Table 15.7. Minomic International: Key Highlights
Table 15.8. Nanostics: Key Highlights
Table 15.9. Tymora Analytical Operations: Key Highlights
Table 15.10. DermTech: Key Highlights
Table 15.11. ICellate Medical: Key Highlights
Table 15.12. VolitionRx: Key Highlights
Table 15.13. OncoDNA: Key Highlights
Table 15.14. LCM Genect: Key Highlights
Table 15.15. Sienna Cancer Diagnostics: Key Highlights
Table 16.1. Liquid Biopsy Developers: Distribution by Year of Establishment
Table 16.2. Liquid Biopsy Developers: Distribution by Company Size and Geographical Location
Table 16.3. Liquid Biopsy Developers: Leading Players
Table 16.4. Liquid Biopsy Products: Distribution by Application Area
Table 16.5. Liquid Biopsy Products: Distribution by Target Cancer Indication
Table 16.6. Liquid Biopsy Products: Distribution by Type of Tumor Marker
Table 16.7. Liquid Biopsy Products: Distribution by Type of Analyte
Table 16.8. Liquid Biopsy Products: Distribution by Type of Status of Development
Table 16.9. Amoy Diagnostics: Annual Revenues, FY2016-FY2018 (CNY Million)
Table 16.10. NeoGenomics: Annual Revenues, 2014 - 2018 (EUR Million)
Table 16.11. QIAGEN: Annual Revenues, 2014 - 2018 (EUR Billion)
Table 16.12. Thermo Fisher Scientific: Annual Revenues, 2014 - 2018 (EUR Billion)
Table 16.13. Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2019
Table 16.14. Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.15. Partnerships and Collaborations: Year-wise Trend by Type of Partnership, 2016-2019
Table 16.16. Partnerships and Collaborations: Distribution by Type of Tumor Marker
Table 16.17. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Tumor Marker
Table 16.18. Partnerships and Collaborations: Distribution by Target Cancer Indication
Table 16.19. Partnerships and Collaborations: Distribution by Type of Partnership and Target Cancer Indication
Table 16.20. Partnerships and Collaborations: Year-wise Trend for Type of Partnership and Target Cancer Indication
Table 16.21. Partnerships and Collaborations: Distribution by Year and Type of Partner
Table 16.22. Most Active Players: Distribution by Number of Partnerships
Table 16.23. Partnerships and Collaborations: Regional Distribution
Table 16.24. Partnerships and Collaborations: Intercontinental and Intracontinental Partnerships
Table 16.25. Funding and Investments: Distribution of Industrial Players by Year of Establishment and Type of Funding, 2015-2019
Table 16.26. Funding and Investments: Cumulative Year-wise Trend, 2015-2019
Table 16.27. Funding and Investments: Cumulative Amount Invested by Year, 2015-2019 (USD Million)
Table 16.28. Funding and Investments: Distribution by Type of Funding, 2015-2019
Table 16.29. Funding and Investments: Distribution Amount Invested and Type of Funding, 2015-2019 (USD Million)
Table 16.30. Funding and Investments: Summary of Investments, 2015-2019 (USD Million)
Table 16.31. Funding and Investments: Distribution by Target Cancer Indication
Table 16.32. Funding and Investments: Distribution by Type of Tumor Marker
Table 16.33. Funding and Investments: Geographical Distribution by Number of Instances
Table 16.34. Funding and Investments: Regional Distribution of Funding Instances
Table 16.35. Most Active Players: Distribution by Amount Invested
Table 16.36. Most Active Investors: Distribution by Number of Instances
Table 16.37. Funding and Investment Summary, 2015-2019 (USD Million)
Table 16.38. Survey Analysis: Distribution by Geography
Table 16.39. Survey Analysis: Distribution by Designation of Respondents
Table 16.40. Survey Analysis: Distribution by Product Portfolio
Table 16.41. Survey Analysis: Distribution by Type of Product / Service Offered
Table 16.42. Survey Analysis: Distribution by Application Area
Table 16.43. Survey Analysis: Distribution by Status of Development of the Product
Table 16.44. Survey Analysis: Likely Size of Liquid Biopsy Products Market (2030)
Table 16.45. Survey Analysis: Likely Size of Other Non-Invasive Cancer Diagnostics Market (2030)
Table 16.46. Global Non-Invasive Cancer Diagnostics Market, 2019-2030 (USD Billion)
Table 16.47. Global Liquid Biopsy Market, 2019-2030 (USD Billion)
Table 16.48. Global Liquid Biopsy Market: Distribution by Application Area, 2019-2030 (USD Billion)
Table 16.49. Global Liquid Biopsy Market for Early Diagnosis, 2019-2030 (USD Billion)
Table 16.50. Global Liquid Biopsy Market for Patient Monitoring, 2019-2030 (USD Billion)
Table 16.51. Global Liquid Biopsy Market for Recurrence Monitoring, 2019-2030 (USD Billion)
Table 16.52. Global Liquid Biopsy Market: Distribution by Target Cancer Indication, 2019-2030 (USD Billion)
Table 16.53. Global Liquid Biopsy Market for Breast Cancer, 2019-2030 (USD Billion)
Table 16.54. Global Liquid Biopsy Market for Lung Cancer, 2019-2030 (USD Billion)
Table 16.55. Global Liquid Biopsy Market for Colorectal Cancer, 2019-2030 (USD Billion)
Table 16.56. Global Liquid Biopsy Market for Prostate Cancer, 2019-2030 (USD Billion)
Table 16.57. Global Liquid Biopsy Market for Bladder Cancer, 2019-2030 (USD Billion)
Table 16.58. Global Liquid Biopsy Market for Melanoma, 2019-2030 (USD Billion)
Table 16.59. Global Liquid Biopsy Market for Gastric Cancer, 2019-2030 (USD Billion)
Table 16.60. Global Liquid Biopsy Market for Pancreatic Cancer, 2019-2030 (USD Billion)
Table 16.61. Global Liquid Biopsy Market for Ovarian Cancer, 2019-2030 (USD Billion)
Table 16.62. Global Liquid Biopsy Market for Other Cancers, 2019-2030 (USD Billion)
Table 16.63. Global Liquid Biopsy Market: Distribution by Type of Tumor Marker, 2019-2030 (USD Billion)
Table 16.64. Global Liquid Biopsy Market for ctDNA, 2019-2030 (USD Billion)
Table 16.65. Global Liquid Biopsy Market for cfDNA, 2019-2030 (USD Billion)
Table 16.66. Global Liquid Biopsy Market for CTCs, 2019-2030 (USD Billion)
Table 16.67. Global Liquid Biopsy Market for Exosomes, 2019-2030 (USD Billion)
Table 16.68. Global Liquid Biopsy Market for Other Tumor Markers, 2019-2030 (USD Billion)
Table 16.69. Global Liquid Biopsy Market: Distribution by Type of Analyte, 2019-2030 (USD Billion)
Table 16.70. Global Liquid Biopsy Market for Blood, 2019-2030 (USD Billion)
Table 16.71. Global Liquid Biopsy Market for Other Body Fluids, 2019-2030 (USD Billion)
Table 16.72. Global Liquid Biopsy Market: Distribution by End Users, 2019-2030 (USD Billion)
Table 16.73. Global Liquid Biopsy Market for Hospitals, 2019-2030 (USD Billion)
Table 16.74. Global Liquid Biopsy Market for Research Institutes, 2019-2030 (USD Billion)
Table 16.75. Global Liquid Biopsy Market for Other End User, 2019-2030 (USD Billion)
Table 16.76. Global Liquid Biopsy Market: Distribution by Geography, 2019-2030 (USD Billion)
Table 16.77. Liquid Biopsy Market in the US, 2019-2030 (USD Billion)
Table 16.78. Liquid Biopsy Market in the UK, 2019-2030 (USD Billion)
Table 16.79. Liquid Biopsy Market in Germany, 2019-2030 (USD Billion)
Table 16.80. Liquid Biopsy Market in Italy, 2019-2030 (USD Billion)
Table 16.81. Liquid Biopsy Market in Spain, 2019-2030 (USD Billion)
Table 16.82. Liquid Biopsy Market in France, 2019-2030 (USD Billion)
Table 16.83. Liquid Biopsy Market in Japan, 2019-2030 (USD Billion)
Table 16.84. Liquid Biopsy Market in Australia, 2019-2030 (USD Billion)
Table 16.85. Liquid Biopsy Market in China, 2019-2030 (USD Billion)
Table 16.86. Liquid Biopsy Market in India, 2019-2030 (USD Billion)
Table 16.87. Liquid Biopsy Market in Rest of the World, 2019-2030 (USD Billion)
Table 16.88. Other Non-Invasive Cancer Diagnostics Market, 2019-2030 (USD Billion)

Note: Product cover images may vary from those shown
  • 360 Capital Partners
  • 4D Lifetec
  • 50K Ventures
  • 5AM Ventures
  • 6 Dimensions Capital
  • A&G Pharmaceutical
  • Abbott
  • Abcodia
  • Accu Reference Medical Lab
  • AccuraGen
  • Ackermans & van Haaren
  • Acobiom
  • Acousys Biodevices
  • Active Motif
  • Acuamark Diagnostics
  • ADC Therapeutics
  • Addario Lung Cancer Medical Institute
  • Admera Health
  • Advanced Wave Sensors
  • Affymetrix
  • AGCT
  • Agena Bioscience
  • Agilent Technologies
  • Agiomix
  • Ahren Innovation Capital
  • Alabama Capital Network
  • Albert & Annas Minne Foundation
  • Alentia Capital Alternativo
  • Alexandria Venture Investments
  • Alliance Global
  • Ally Bridge Group
  • Alychlo
  • Amadix
  • AMAL Therapeutics
  • Amazon
  • Amedes Group
  • Amer International Group
  • America’s Choice Provider Network
  • American Bio Services
  • Amgen
  • Amoy Diagnostics
  • Anchor Molecular
  • ANCON Medical
  • Andreessen Horowitz
  • ANGLE
  • Anixa Biosciences
  • Annoroad Gene Technology
  • Anpac Bio
  • Anthill Ventures
  • Apostle
  • Arboretum Ventures
  • ARCH Venture Partners
  • ArcherDX
  • ARNA Genomics
  • Arquer Diagnostics
  • ArrayGenomics
  • Arrow Diagnostics
  • Artiman Ventures
  • ARUP Laboratories
  • ASB Ventures
  • Asia Genomics
  • ASPiRA LABS
  • AstraZeneca
  • Astrimmune
  • Asuragen
  • Aurum Ventures
  • AVIVA Biosciences
  • Balderton Capital
  • Bangkok Molecular Genetics
  • BARD1 Life Sciences
  • BeAble Capital
  • BeaconLBS
  • Bellwether Bio
  • Best Med Opinion
  • Beth Israel Deaconess Medical Center
  • Betta Pharmaceuticals
  • Bezos Expeditions
  • BGI Genomics
  • Bill & Melinda Gates Foundation
  • Biocartis
  • Biocept
  • BioChain
  • Biodesix
  • BioDiscovery
  • Bioeconomy Capital
  • BioFluidica
  • BIOHAL
  • BioHisto Maroc
  • Biolidics
  • Biological Dynamics
  • BioMarCare Technologies
  • BioMark Diagnostics
  • BiomaRx
  • BIOPROGNOS
  • Bio-Rad Laboratories
  • Biosearch Technologies
  • BioSequence
  • BioVeda China Fund (BVCF)
  • BioVendor
  • BioView
  • Bioyong Technology
  • BloodPAC
  • Blue Pool Capital
  • Bluestar Genomics
  • BNO BIO
  • Boehringer Ingelheim
  • Boreal Genomics
  • Boston Children’s Hospital
  • Breath Diagnostics
  • BrightEdge Ventures
  • Bristol-Myers Squibb
  • BSN
  • Burning Rock Biotech
  • Cambridge Epigenetix
  • Cambridge Innovation Capital
  • Cambridge University
  • CANCER-ID
  • Canostix
  • Capio Biosciences
  • Capital Research and Management
  • CareFirst BlueCross BlueShield
  • Caris Life Sciences
  • Cathay Fortune International
  • CDBI Partners
  • Celgene
  • CellMax Life
  • Celsee
  • Checkmate Pharmaceuticals
  • China Biotech Services
  • China Merchants Securities International
  • Chronix Biomedical
  • CIRCULOGENE
  • Cirina
  • Cleveland Diagnostics
  • Clinical Genomics
  • Clinomics
  • CloudHealth Genomics
  • Cloudstone Venture Fund
  • Co-Diagnostics
  • Colorectal Cancer Alliance
  • ConquerX
  • CORE Diagnostics
  • Cornerstone Total Return Fund
  • Cowin Venture Capital
  • CPH Capital
  • CryoGene
  • Cyclomics
  • Cynvenio-Livzon Diagnostics
  • Cytofind Diagnostics
  • Cytosystems
  • Data Collective
  • Datar Cancer Genetics
  • Decheng Capital
  • Delee
  • Denlux Capital
  • DermTech
  • DiaCarta
  • DiaDx
  • Diagnolita
  • Diagnostics Development Hub
  • DIAN Diagnostics
  • Diatech Pharmacogenetics
  • DiuVita Diagnostics
  • DNA Labs India
  • Dow Biomedica
  • DT Capital
  • Durviz
  • EarlyDx
  • EDP Biotech
  • EKF Diagnostics
  • Elypta
  • EONE Diagnomics Genome Center
  • Epic Sciences
  • Epigenomics
  • Eurobio Scientific
  • Eurofins Biomnis
  • European Association for Predictive, Preventive & Personalised Medicine
  • European Commission
  • European Organisation for Research and Treatment of Cancer
  • Exact Sciences
  • Exalt Diagnostics
  • ExBiome
  • Exosome Diagnostics
  • Exosomics
  • Expedeon
  • Fårö Capital
  • Flagship Biosciences
  • Fluxion Biosciences
  • Fortune Fountain Capital
  • Fosun Pharmaceutical
  • Foundation Medicine
  • Fountain Medical Development
  • Fox Chase Cancer Center
  • Franklin Templeton Investments
  • Frederick National Laboratory for Cancer Research
  • Freenome
  • Fudan-Taizhou Institute of Health Sciences
  • GEM Global Yield Fund
  • GeneCast Biotechnology
  • Generation Investment Management
  • Geneseq Biosciences
  • Genetics Research
  • Genetracer Biotech
  • GENEWIZ
  • GENEXT
  • Genomenon
  • Genomic Health
  • Genomics England
  • Genomictree
  • Genoptix
  • Genostics
  • GILUPI
  • Glycanostics
  • Good Health Capital
  • GRAIL
  • Great Lakes New England Clinical Validation Center
  • Green Pine Capital Partners
  • Guangzhou Wondfo Biotech
  • Guardant Health
  • Gunnar Nilsson Cancer Foundation
  • GV
  • Hadean Ventures
  • HaploX
  • HarlePhil Ventures
  • HDFC
  • HealthCor Partners Management
  • HEDA Ventures
  • Helice Genomic Sciences
  • Helsinn Investment Fund
  • Highlight Capital
  • Hillhouse Capital Group
  • hrmed.tech
  • HuangPu River Capital (HPR)
  • Hummingbird Diagnostics
  • Hvidovre Hospital
  • Hyderabad Angels
  • ICBC International
  • iCellate Medical
  • Idinvest Partners
  • iGenetic Diagnostics
  • Ikonisys
  • Illumina
  • Immodulon Therapeutics
  • Impact Lab
  • Imperial Innovations
  • IncellDx
  • Indian Angel Network
  • Inivata
  • Innovative Diagnostic Laboratory
  • Innovatus Capital Partners
  • Inova Strategic Investments
  • Inovio Pharmaceuticals
  • Institut Jules Bordet
  • Integrated Diagnostics Holdings
  • International Medical Center
  • Interpace Diagnostics
  • Intezyne
  • Inventures
  • Invitek Molecular
  • Invoke Capital
  • IP Group
  • BIO.be
  • IPS Genomix
  • IV Diagnostics
  • Janssen Diagnostics
  • Jennison Associates
  • Johnson & Johnson Innovation
  • Jointown Pharmaceutical Group
  • JTS Health Partners
  • Junson Capital
  • Kaiser Permanente Ventures
  • KEODES
  • Kexin Capital
  • LABLAB
  • Laboratory for Advanced Medicine
  • Lariat Biosciences
  • Levine Cancer Institute
  • Lexent Bio
  • LifeArc
  • LifeX
  • Lilly Asia Ventures
  • Limitless Earth
  • Liquid Biotech
  • Lonza
  • Loyal Valley Capital
  • LU Holding
  • Lucence Diagnostics
  • LungLife AI
  • MagBio Genomics
  • Martell Biosystems
  • Maryland Venture Fund
  • Mascots Medical and Laboratory Center
  • Massive Genomics
  • Matrix Partners China
  • Mayo Clinic
  • McKesson Ventures
  • MDNA Life Sciences
  • MDxHealth
  • MedCDx
  • MedGenome
  • Medigen Biotechnology
  • MediNcrease Health Plans
  • MedStar Health
  • Menarini Silicon Biosystems
  • Merck
  • Mercy BioAnalytics
  • Metabolomic Technologies
  • Metamark
  • MGI Tech
  • MiCareo
  • Microgenomics
  • Micromedic Technologies
  • Milost Global
  • Miltenyi Biotec
  • Mindera
  • Ministry of Health Singapore
  • Minomic International
  • MIODx
  • miR Scientific
  • MiRXES
  • MolecularMatch
  • MolecularMD
  • MRM Proteomics
  • multimmune
  • Mumbai Angels
  • Mursla
  • Myriad Genetics
  • Nan Fung Group
  • Nanjing Kaiyuan Growth Capital Investments
  • Nanostics
  • NantHealth
  • Natera
  • National Cancer Institute
  • National Institutes of Health
  • National Taiwan University
  • Naveris
  • NEO New Oncology
  • NeoGeneStar
  • NeoGenomics
  • Neon Therapeutics
  • Netherlands Organization for Scientific Research
  • NeuMoDx
  • New Enterprise Associates
  • New Jersey Economic Development Authority
  • New Science Ventures
  • NIRAMAI Health Analytix
  • NM Genomix
  • Nodexus
  • N-of-One
  • Nonacus
  • Norgen Biotek
  • North Carolina Biotechnology Center
  • Novartis
  • Novigenix
  • nRichDX
  • Nucleix
  • NueHealth
  • NuGEN
  • NuView Life Sciences
  • NVIGEN
  • OHSU Knight Cancer Institute
  • oncgnostics
  • Oncimmune
  • OncoCyte
  • Oncode Institute
  • Oncode Scientific
  • OncoDNA
  • Oncolys BioPharma
  • Oncore Pharma
  • OncoSeek
  • OPKO Health
  • OrbiMed Advisors
  • Örebro University Hospital
  • ORI Healthcare Fund
  • Owlstone Medical
  • Oxford Gene Technology
  • Pacific Edge
  • PANAGENE
  • Pangaea Oncology
  • Pantai Premier Pathology
  • Paragon Genomics
  • Parampara Fund
  • ParkwayHealth Laboratory
  • PathGroup
  • Perceptive Advisors
  • PeriRx
  • Personal Genome Diagnostics
  • Pfizer
  • Pillar Biosciences
  • pluriSelect Life Science
  • Polaris Partners
  • Polymedco
  • Polymer Char
  • Positive Bioscience
  • Precipio
  • Precision for Medicine
  • Predicine
  • Prescient Metabiomics
  • Prevail Partners
  • Prime Value Capital Management
  • Progenetics
  • Prognos
  • Prosperico Venture
  • Protagen Diagnostics
  • PROVIDENS
  • Provista Diagnostics
  • QIAGEN
  • Qianjiang Capital
  • Quantitative Cancer Diagnostix (QCDx)
  • Quest Diagnostics
  • Quidel
  • RA Capital Management
  • RainDance Technologies
  • Rarecells Diagnostics
  • RareCyte
  • Regionalt Cancercentrum
  • Reig Jofre Future Health
  • Resolution Bioscience
  • ResourcePath
  • RGCC Group
  • Roche
  • Rongsheng Investment
  • R-Pharm
  • RT Ventures
  • Sabartech
  • SAGA Diagnostics
  • Saha Fund
  • Sambrinvest
  • Sangel Capital
  • SanoLiBio
  • Sarah Cannon Research Institute
  • Savicell Diagnostics
  • Savran Technologies
  • SB China Venture Capital
  • ScreenCell
  • Seer
  • Sequoia Capital
  • SeraCare Life Sciences
  • Sevident
  • Shanghai Fosun Long March Medical Science
  • Shenzhen Innovation Investment Group
  • Sienna Cancer Diagnostics
  • Simfo
  • Singapore Diagnostics
  • Singlera Genomics
  • Skåne University Hospital
  • Société Régionale d'Investissement de Wallonie (SRIW)
  • Sofina
  • Sofinim
  • Sofinnova Ventures
  • SOPHiA GENETICS
  • Speclipse
  • StageZero Life Sciences
  • STEMCELL Technologies
  • Strand Life Sciences
  • StrandSmart
  • Streck
  • Stroke Detection Plus
  • Sungent BioVenture
  • Sutter Hill Ventures
  • Suzhou Kintor Pharmaceuticals
  • Swift Biosciences
  • Syncona Partners
  • Sysmex Inostics
  • T Rowe Price Associates
  • Taiwan Government Industrial Development Bureau, Ministry of Economic     
  • Takara Bio
  • TAKE2
  • Takeda
  • Tarvand Sina Tajhiz
  • TATAA Biocenter
  • Tech Transfer UPV
  • Telegraph Hill Partners
  • Temasek
  • Tempus
  • Tencent
  • The Heritage Group
  • The University of Texas MD Anderson Cancer Center
  • The W Fund
  • Theranosis Life Sciences
  • Thermo Fisher Scientific
  • THG Ventures
  • Thrive Earlier Detection
  • Todos Medical
  • Torna Kapital
  • Torpedo Diagnostics
  • Tranzend
  • TSH Biopharm
  • Tymora Analytical Operations
  • UCF Medical Investment
  • United States Department of Veterans Affairs
  • Unitus Ventures
  • Universal Diagnostics
  • University Campus Bio-Medico of Rome
  • University of Alabama at Birmingham
  • University of Minnesota
  • University of Texas Health Science Center
  • Varian Medical Systems
  • Velox Biosystems
  • Verily Life Sciences
  • Viatar CTC Solutions
  • Vienomics
  • Vigilant Biosciences
  • Vinsovier
  • VisionGate
  • VolitionRx
  • Vortex Biosciences
  • West Cancer Center
  • Windham Venture Partners
  • Wisemont Capital
  • WntResearch
  • Woodford Patient Capital Trust
  • WRF Capital
  • WS Investment
  • WuXi NextCODE
  • XboXLab
  • X-ZELL
  • Yahui Precision Medical Fund
  • Yale School of Medicine
  • Yi Fang Group
  • Zehou Capital
  • Zinexts Life Science
  • Zodius
  • Zogen Genética Molecular
Note: Product cover images may vary from those shown

 

 

Loading
LOADING...

Adroll
adroll